Nypro Japan cancels contract on recombinant human albumin with Bipha Co., a subsidiary of Tanabe Mitsubishi

The contract was concluded in 2001. Tanabe Mitsubishi acquired registration of recombinant albumin in 2007, but recognition was withdrawn in 2009 following clinical trials. Since then, bulk supply for research was also stopped. All stocks held by Nypro in Bipha Co. are transferred to Tanabe Mitsubishi

Nipro press release, August 31, 2012

Nypro Japan cancels contract on recombinant human albumin with Bipha Co., a subsidiary of Tanabe Mitsubishi
Scroll to top